Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Use of Teriparatide to Accelerate Fracture Healing

This study has been terminated.
(The study was terminated due to poor enrollment.)
Sponsor:
Collaborators:
Information provided by (Responsible Party):
University of Rochester
ClinicalTrials.gov Identifier:
NCT00594906
First received: January 7, 2008
Last updated: March 14, 2013
Last verified: March 2013

January 7, 2008
March 14, 2013
January 2008
July 2012   (final data collection date for primary outcome measure)
Healing of a Fracture From a Low Energy Fall [ Time Frame: Measured at 16 weeks ] [ Designated as safety issue: No ]
Callus formation at the fracture site as defined by a CT scan to determine healing (early/beginning callus formation) or healed (complete callus formation)
Accelerated fracture healing of low energy fragility fractures based on motion analysis measurement. [ Time Frame: 0, 4, 8, 12 & 16 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00594906 on ClinicalTrials.gov Archive Site
Not Provided
Radiologic evidence of callus formation. [ Time Frame: 0 & 16 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Use of Teriparatide to Accelerate Fracture Healing
Use of Teriparatide to Accelerate Fracture Healing

The purpose of this study is to compare the effect of the drug teriparatide to the effect of placebo on pelvic fracture healing.

Teriparatide is a man-made form of a naturally occurring hormone called parathyroid. It increases bone density and bone strength to help prevent fractures and can be used to treat osteoporosis in people who have a high risk of bone fracture. The purpose of this study is to compare the effect of teriparatide to the effect of placebo on pelvic fracture healing.

This study will last 16 weeks. Participants will be randomly assigned to receive either teriparatide or placebo for the duration of the study. Participants will also be given calcium and vitamin D supplements to take daily throughout the study. At 4-week intervals, participants will undergo functional evaluations that will include the instrumented sit-to-stand test, the timed-up-and-go, and a gait velocity test. Participants will also undergo a DXA scan upon enrollment; undergo a CT evaluation upon enrollment and 16 weeks post-fracture; and complete specific pain, self-perceived function, mental status, and depression scales throughout the study.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Pelvic Fracture
  • Drug: Teriparatide
    Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
    Other Name: Forteo
  • Drug: Placebo
    Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
  • Active Comparator: Injection
    30 participants will receive teriparatide (Forteo) injection pens.
    Intervention: Drug: Teriparatide
  • Placebo Comparator: Placebo
    30 participants will receive placebo injection pens.
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
10
July 2012
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Females must be menopausal (no menses within the last 12 months)
  • Low energy fragility fractures of the pelvis, including anterior column, posterior column, inferior or superior rami, or sacrum
  • Maximum of 2 weeks post fracture
  • Mental status consistent with completing the study protocol

Exclusion Criteria:

  • Currently receiving any treatment for osteoporosis, including estrogen and estrogenic-like compounds
  • Received radiation treatment to any site at any time in the past
  • Received chemotherapy for cancer at any time in the past
  • Any active cancer
  • Surgical repair (or attempted repair) of the fracture site in the pelvis
  • Use of any bone-active medications
  • Use of anticonvulsant therapy
  • Use of immunosuppressants
  • Any renal, gastrointestinal, liver, or metabolic bone disease
  • Pregnancy
  • High calcium, parathyroid hormone, or alkaline phosphatase, as based on laboratory results
Both
55 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00594906
P50 AR054041, P50AR054041
No
University of Rochester
University of Rochester
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  • National Institutes of Health (NIH)
Principal Investigator: J.Edward Puzas, PhD University of Rochester
University of Rochester
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP